NeRRe Therapeutics Company

Neurokinin treatment for refractory and/or chronic cough. NeRRe Therapeutics is a clinical-stage company developing a unique pipeline of three neurokinin -1 receptor antagonists (NK-1RAs) for the treatment of common, chronic and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction. Their focus with NeRRe’s lead NK-1 antagonist orvepitant is on Refractory or Unexplained Chronic Cough (RUCC).
Technology: AgeTech Companies
Industry: Healthcare
Headquarters: United Kingdom
Founded Date: 2012
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 7
Total Funding: $47M
Estimated Revenue: $1M to $10M
Last Funding Type: Series B

Visit Website
Register and Claim Ownership